Loading clinical trials...
Loading clinical trials...
Objective of this 16-week, open-label study is to assess the safety and tolerability of once daily application of three doses of STS during continuous dosing in the treatment of elderly subjects with ...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Somerset Pharmaceuticals
NCT04480918 · Treatment Resistant Depression, Major Depressive Episode, and more
NCT06732284 · Major Depression, Sleep Inertia
NCT02434393 · Major Depression, Late Life Depression (LLD)
NCT07031817 · Bipolar Disorder (BD), Major Depressive Episode (MDE), and more
NCT06763081 · Behavioral Activation, Major Depressive Disorder, and more
Mohammed Bari, M.D.
Chula Vista, California
Charles Meredith, M.D.
San Diego, California
Daniel Zimbroff, M.D.
Upland, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions